Lancet Oncol 2023修正；24: 1181 - 95

The Lancet Oncology Pub Date : 2024-12-02 DOI:10.1016/s1470-2045(24)00650-8

{"title":"Lancet Oncol 2023修正；24: 1181 - 95","authors":"","doi":"10.1016/s1470-2045(24)00650-8","DOIUrl":null,"url":null,"abstract":"Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1181–95—In figure 2D of this Article, the datapoint showing the hazard ratio for no liver metastases was omitted. This correction has been made to the online version as of Dec 2, 2024.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"37 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Oncol 2023; 24: 1181–95\",\"authors\":\"\",\"doi\":\"10.1016/s1470-2045(24)00650-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1181–95—In figure 2D of this Article, the datapoint showing the hazard ratio for no liver metastases was omitted. This correction has been made to the online version as of Dec 2, 2024.\",\"PeriodicalId\":22865,\"journal\":{\"name\":\"The Lancet Oncology\",\"volume\":\"37 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1470-2045(24)00650-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(24)00650-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Rha SY, Oh DY, Yañez P，等。Pembrolizumab +化疗vs安慰剂+化疗治疗her2阴性晚期胃癌（KEYNOTE-859）：一项多中心、随机、双盲、3期试验柳叶刀肿瘤学杂志2023；[24:1181 - 95]在本文的图2D中，省略了显示无肝转移的风险比的数据点。此更正已于2024年12月2日对在线版本进行了修改。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to Lancet Oncol 2023; 24: 1181–95

Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1181–95—In figure 2D of this Article, the datapoint showing the hazard ratio for no liver metastases was omitted. This correction has been made to the online version as of Dec 2, 2024.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Lancet Oncology

自引率

0.00%

发文量